At present, the most effective chemotherapeutic drugs for NSCLC are gefitinib, erlotinib, and afatinib, which are highly targeted EGFR-directed tyrosine kinase inhibitors (TKIs) [4]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.